Business Wire

Lunaphore appoints Janis Taube, M.D., M.Sc., to Scientific Advisory Board

Share

Lunaphore, a Swiss life sciences company developing technology to enable spatial biology in every laboratory, today announced the appointment of Janis M. Taube, M.D., M.Sc., a leading pathologist and expert on immunotherapy research, to its Scientific Advisory Board. As an advisor, Dr. Taube will provide strategic advisory support to Lunaphore’s scientific activities and product portfolio development.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220119005555/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Janis Taube, M.D., M.Sc. (Photo: Lunaphore)

“Janis is a trailblazer and highly regarded expert in pathology and immunotherapy research, and we are excited to work with her to build visibility of our products in laboratories around the world,” said Diego G. Dupouy, Ph.D., Chief Technology Officer of Lunaphore. “We are proud to have convened a world-class group of scientific advisors to help advance our scientific and product development strategy.”

Dr. Taube is the Director of the Dermatopathology division of Johns Hopkins Hospital in Baltimore, MD. She also serves as a Professor of Dermatology, Professor of Oncology, and Professor of Pathology at the Johns Hopkins University School of Medicine. Dr. Taube holds additional roles as Co-Director of the Tumor Microenvironment Laboratory at the Bloomberg~Kimmel Institute for Cancer Immunotherapy as well as Co-Director of the Mark Foundation Center for Advanced Genomics and Imaging.

Her research primarily focuses on immune evasion by solid tumors—specifically studying the PD-1/PD-L1 axis—and the identification of potential biomarkers that predict response to novel immunotherapies. She developed the PD-L1 immunohistochemical assay and scoring system for the first in-human anti-PD-1 and anti-PD-L1 clinical trials, versions of which are now FDA approved and mainstays of cancer treatment.

“I firmly believe that the next generation of biomarkers will involve spatially resolved and quantitative analysis of the immunological landscape of tumors,” said Dr. Taube.

Dr. Taube earned an M.D. at Tulane University School of Medicine and completed her residency in anatomic pathology at Johns Hopkins University School of Medicine. She completed a fellowship in dermatopathology at Stanford University School of Medicine.

To learn more about Lunaphore, please visit: https://lunaphore.com/

Disclaimer:

1 Participation by Janis Taube as an advisor to Lunaphore does not constitute or imply endorsement of Lunaphore by Johns Hopkins University.

About Lunaphore

Lunaphore Technologies S.A. is a Swiss company born in 2014 with the vision of enabling spatial biology in every laboratory. Lunaphore has developed a game-changing chip technology which can extract spatial proteomic and genomic data from tumors and transform any simple assay into multiplex spatial biology without complexity. Lunaphore empowers researchers to push the boundaries of research to ultimately develop the next generation personalized therapies. For further information on Lunaphore and its products, please visit www.lunaphore.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

For further information contact:
Irene Tamayo
Lunaphore Corporate Communications
Email: communications@lunaphore.com

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Antech’s breakthrough cancer screening tool launches in Europe, supporting early canine cancer detection23.4.2024 08:00:00 CEST | Press release

Antech, the veterinary diagnostics company focused on partnering with veterinary professionals to predict, diagnose, and monitor wellness and disease, today announced the launch of the breakthrough in-hospital Nu.Q® Canine Cancer Test in Europe. A rapid, accurate, targeted cancer screening tool for high-risk breeds and older dogs, Nu.Q® testing also includes prevalent types of canine cancers, enabling veterinarians and pet owners to make informed decisions about cancer care more quickly. Jimmy Barr, DVM, DACVECC, Chief Medical Officer at Antech, part of Mars Science & Diagnostics said: “It’s exciting to see innovations like Nu.Q® Canine Cancer Test become more widely available to veterinary teams in Europe. With cancer affecting one in four dogs1, it is critical that veterinary professionals have access to fast and accurate cancer screening methods, so they can make informed and timely decisions and ultimately change pet health outcomes. This is what our work at Antech is all about.” N

ReNAgade Therapeutics Announces Presentations at the ASGCT 27 th Annual Meeting22.4.2024 22:46:00 CEST | Press release

ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines, today announced an oral and poster presentation highlighting preclinical data supporting its comprehensive RNA technology platform at the American Society of Gene & Cell Therapy (ASGCT) 27th Annual Meeting being held May 7-11, 2024, in Baltimore, Maryland. “We are excited to highlight foundational research and development advancements at ASGCT supported by our poster presentation illuminating ReNAgade’s continued work in validating our immune tropic LNP-based delivery systems in NHPs with broad potential applications in oncology and autoimmune diseases,” said Pete Smith, Ph.D., Chief Scientific Officer of ReNAgade. “Additionally, our oral presentation demonstrates a non-viral, all-RNA gene editing system enabling in vivo, exon-sized insertion and probable re-dosing with the goal of higher specificity and a better safety profile when used in the clinical setting. Together, these promising data are anot

Nominal Emerges From Stealth With Backing From General Catalyst, Lux Capital, Founders Fund, for Navigating Mission-Critical Data Analytics22.4.2024 19:28:00 CEST | Press release

Nominal, a company specializing in creating end-to-end data analysis solutions for industrial engineering teams, emerged from stealth to provide a faster, more reliable way to review test data and validate mission-critical systems. The startup raised $7.5M in Seed funding led by Lux Capital with support from Founders Fund and $20M in their Series A led by General Catalyst. Additional investors include Haystack VC, XYZ Ventures, Human Capital, Box Group, and Overmatch. Nominal specializes in creating software solutions for the Aerospace, Defense, Industrial Machinery, Transportation, and Energy sectors with various partnerships across the U.S. government. The company is led by co-founder and CEO Cameron McCord, who has extensive experience in the private sector at prominent startups Anduril, Applied Intuition, and Saildrone and as a venture capitalist, and in the public sector as a veteran Nuclear Submarine Officer and Congressional Liaison for the Navy. McCord works closely with his co

Green Street Expands Private Market Research & Data Solution with New Global Data Center and Lodging Coverage22.4.2024 15:02:00 CEST | Press release

Green Street, the preeminent provider of commercial real estate intelligence, has released expanded market data and analytics with the addition of Data Center and Lodging sector coverage. The new insights include Sector Outlook reports that provide a deep dive into demand and supply dynamics, operating fundamentals, valuations, and return expectations across a comprehensive set of top markets. Green Street’s private market research and data suite now covers nine sectors in the U.S. and six sectors in Europe. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240422790727/en/ Green Street Expands Private Market Research & Data Solution with New Global Data Center and Lodging Coverage (Graphic: Business Wire) “Investor perception of data center real estate has transitioned to ‘must have’ in the past few years. With sweeping digitization trends and its secular demand story in full bloom, the data center sector has years of optimism

Lenovo Announces LISSA: New AI-powered Capability That Helps Businesses Reduce IT Footprint22.4.2024 15:00:00 CEST | Press release

A new Lenovo AI-powered sustainability engine empowers businesses to help make more data-driven and sustainable IT buying decisions. Lenovo’s Intelligent Sustainability Solutions Advisor (LISSA) gives customers actionable sustainability insights to understand their estimated emissions impact across their IT lifecycle and deploy customized solutions that align with their sustainability goals. Through Generative AI, LISSA offers visibility into the estimated carbon emissions associated with various Lenovo sustainabilty solutions such as TruScale Device as a Service (DaaS), Asset Recovery, packaging efficiencies, lower-carbon shipping options, lifecycle extensions, certified refurbishment, and more. Additionally, LISSA helps to simulate multiple solution pathways and identify potential emissions reduction opportunities to support the customer’s IT decarbonization goals in the digital workplace. In a recent survey1, 87% of executives indicated they believe AI enables the potential to addre

HiddenA line styled icon from Orion Icon Library.Eye